CATALOGO DEI PRODOTTI DELLA RICERCA

MAURELLI, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.330
NA - Nord America 1.997
AS - Asia 1.664
SA - Sud America 241
AF - Africa 74
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.321
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.940
RU - Federazione Russa 1.012
SG - Singapore 653
CN - Cina 348
IT - Italia 247
HK - Hong Kong 212
GB - Regno Unito 210
DE - Germania 204
BR - Brasile 203
IE - Irlanda 150
FR - Francia 141
SE - Svezia 115
FI - Finlandia 101
VN - Vietnam 90
IN - India 72
KR - Corea 70
JP - Giappone 63
ID - Indonesia 42
NL - Olanda 34
CA - Canada 31
ES - Italia 27
SA - Arabia Saudita 25
TG - Togo 25
TR - Turchia 20
BJ - Benin 19
AT - Austria 18
UA - Ucraina 18
AR - Argentina 17
MX - Messico 17
BE - Belgio 12
AU - Australia 8
EG - Egitto 8
IQ - Iraq 8
IR - Iran 8
ZA - Sudafrica 8
BD - Bangladesh 7
HU - Ungheria 7
PL - Polonia 7
EC - Ecuador 6
IL - Israele 6
TW - Taiwan 6
KE - Kenya 5
CL - Cile 4
MY - Malesia 4
NZ - Nuova Zelanda 4
BG - Bulgaria 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
GR - Grecia 3
LB - Libano 3
LK - Sri Lanka 3
PK - Pakistan 3
UY - Uruguay 3
AG - Antigua e Barbuda 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
JO - Giordania 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BW - Botswana 1
CY - Cipro 1
DZ - Algeria 1
GF - Guiana Francese 1
HN - Honduras 1
HR - Croazia 1
LU - Lussemburgo 1
LV - Lettonia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PF - Polinesia Francese 1
PH - Filippine 1
PY - Paraguay 1
RW - Ruanda 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.321
Salva come PNG Salva come JPEG
Città #
Dallas 625
Moscow 357
Singapore 245
Chandler 244
Hong Kong 208
Ashburn 173
Dublin 138
Munich 110
Beijing 93
Southend 87
Helsinki 68
New York 48
Los Angeles 47
London 43
Jacksonville 42
Ho Chi Minh City 40
Verona 37
Lawrence 34
Princeton 34
Redondo Beach 30
Wilmington 28
Jakarta 27
Buffalo 26
Lomé 25
Milan 25
Paris 25
Amsterdam 23
São Paulo 21
Riyadh 20
Sindelfingen 20
Woodbridge 20
Cotonou 19
Lappeenranta 18
Rome 18
Washington 18
Chennai 17
Jinan 16
Monza 16
Santa Clara 16
Seattle 16
Manchester 15
Tokyo 15
Hanoi 14
Madrid 14
Nuremberg 14
Houston 13
Mumbai 13
Bologna 12
Boston 12
Bethnal Green 11
Chicago 11
Frankfurt am Main 11
Ghaziabad 11
Ann Arbor 10
Liverpool 10
Nanjing 10
Guangzhou 9
Phoenix 9
The Dalles 9
Ankara 8
Brasília 8
Dongguan 8
Montreal 8
Redwood City 8
Chieri 7
Fairfield 7
Giza 7
Haiphong 7
Marseille 7
Shanghai 7
Tianjin 7
Vancouver 7
Wakabadai 7
Warsaw 7
Atlanta 6
Brussels 6
Budapest 6
Gurugram 6
Igusa 6
Jyväskylä 6
Mexico City 6
Minamimotomachi 6
Stockholm 6
Toronto 6
Vienna 6
Bari 5
Belo Horizonte 5
Brindisi 5
Brooklyn 5
Coquitlam 5
Hanover 5
Hyderabad 5
Konya 5
Orem 5
Redmond 5
San Jose 5
Shenyang 5
Berlin 4
Changsha 4
Columbus 4
Totale 3.588
Salva come PNG Salva come JPEG
Nome #
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 294
A systematic review of treatments for pityriasis lichenoides 275
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study 196
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study 154
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 141
Acquired perforating dermatoses show increased levels of cutaneous advanced glycation end-products 138
BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. 134
Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review 130
Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid 128
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 122
Psoriasin (S100A7) is increased in serum of patients with moderate to severe psoriasis 122
A case of genital primary syphilis with superimposed impetigo 121
Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature 117
Gender perspective in the management of psoriasis 116
Amicrobial Pustulosis of the Folds: Report of Three New Cases 114
Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature 113
A man with a widespread bullous eruption 110
Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study 107
Adrenergic urticaria successfully treated with omalizumab 107
Annular Erythema: New and Revisited Variants 102
Advanced Glycation End Products and Psoriasis 101
Neutrophilic figurate erythema: report of a new case in an adult and comparison between adult and paediatric cases 101
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease 100
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis 98
Biological agents targeting interleukin-13 for atopic dermatitis 98
Clinical profile and co-infections of urethritis in males 96
Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis 94
Price variability of TNF-α inhibitor biosimilars among European countries 91
Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series 90
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 88
Idiopathic lichenoid and granulomatous dermatitis 86
Interferon-beta injection site reactions in patients with multiple sclerosis. 85
Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination 83
Milia-like calcinosis cutis in Down syndrome: a new case with a review of the literature 83
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo 81
Atopic Dermatitis in the Elderly Population 80
null 80
Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients 76
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis 75
Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines 75
Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin 74
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 71
Uncommon Non‑Infectious Annular Dermatoses 70
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients 68
Visual Vignette 67
Managing the Patient with Psoriasis and Metabolic Comorbidities 66
Eosinophilic annular erythema successfully treated with cyclosporine 66
Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study 65
Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab 65
IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review 65
The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases 64
Long‑Term Effectiveness and Safety of Ixekizumab for the Treatment of moderate‑to‑Severe Plaque Psoriasis: A Five‑Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 63
Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle 63
Palisaded neutrophilic granulomatous dermatitis and its associations with autoimmune diseases 62
Pruritus as a Distinctive Feature of Type 2 Inflammation 58
Targeting IL-4 for the Treatment of Atopic Dermatitis 58
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 56
Tailored biological treatment for patients with moderate-to-severe psoriasis 55
Is risankizumab as needed administration a good option for patients with plaque psoriasis? 55
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) 52
Efcacy and safety of JAK inhibitors in patients aged >60 years with moderate‐to‐severe atopic dermatitis: a 52‐week multicenter, real‐life study—IL AD (Italian Landscape Atopic Dermatitis) 51
Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience 50
Lymphoplasmacytic plaque effectively treated with imiquimod 49
Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment 47
The Combination of Dupilumab with Other Monoclonal Antibodies 45
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS) 44
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis 41
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 37
Overview of Atopic Dermatitis in Different Ethnic Groups 37
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis 37
Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260‐Week Real‐World Multicenter Retrospective Study Exploring the Role of Concomitant PsA–IL PSO (Italian Landscape Psoriasis) 35
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 35
Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study 19
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 11
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study 9
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 5
Totale 6.417
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.876
article - articoli 24.461
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 415
Totale 49.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202177 0 0 0 0 19 16 10 1 6 2 13 10
2021/2022228 13 26 0 18 31 6 6 23 4 14 30 57
2022/2023738 38 68 63 134 58 187 16 34 90 13 25 12
2023/2024647 16 30 56 51 52 126 115 42 8 39 71 41
2024/20251.894 119 63 98 291 80 115 168 111 244 136 143 326
2025/20262.554 293 169 674 610 808 0 0 0 0 0 0 0
Totale 6.417